Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

F. Bovis, T. Kalincik, F. Lublin, G. Cutter, C. Malpas, D. Horakova, E.K. Havrdova, M. Trojano, A. Prat, M. Girard, P. Duquette, M. Onofrj, A. Lugaresi, G. Izquierdo, S. Eichau, F. Patti, M. Terzi, P. Grammond, R. Bergamaschi, P. SolaD. Ferraro, S. Ozakbas, G. Iuliano, C. Boz, R. Hupperts, F. Grand'Maison, C. Oreja-Guevara, V. van Pesch, E. Cartechini, T. Petersen, A. Altintas, A. Soysal, C. Ramo-Tello, P. McCombe, R. Turkoglu, H. Butzkueven, J.S. Wolinsky, C. Solaro, M.P. Sormani

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To compare the effectiveness of glatiramer acetate (GA) vs intramuscular interferon beta-1a (IFN-β-1a), we applied a previously published statistical method aimed at identifying patients' profiles associated with efficacy of treatments. METHODS: Data from 2 independent multiple sclerosis datasets, a randomized study (the Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis [CombiRx] trial, evaluating GA vs IFN-β-1a) and an observational cohort extracted from MSBase, were used to build and validate a treatment response score, regressing annualized relapse rates (ARRs) on a set of baseline predictors. RESULTS: The overall ARR ratio of GA to IFN-β-1a in the CombiRx trial was 0.72. The response score (made up of a linear combination of age, sex, relapses in the previous year, disease duration, and Expanded Disability Status Scale score) detected differential response of GA vs IFN-β-1a: in the trial, patients with the largest benefit from GA vs IFN-β-1a (lower score quartile) had an ARR ratio of 0.40 (95% confidence interval [CI] 0.25-0.63), those in the 2 middle quartiles of 0.90 (95% CI 0.61-1.34), and those in the upper quartile of 1.14 (95% CI 0.59-2.18) (heterogeneity p = 0.012); this result was validated on MSBase, with the corresponding ARR ratios of 0.58 (95% CI 0.46-0.72), 0.92 (95% CI 0.77-1.09,) and 1.29 (95% CI 0.97-1.71); heterogeneity p <0.0001). CONCLUSIONS: We demonstrate the possibility of a criterion, based on patients' characteristics, to choose whether to treat with GA or IFN-β-1a. This result, replicated on an independent real-life cohort, may have implications for clinical decisions in everyday clinical practice. © 2020 American Academy of Neurology.
Original languageEnglish
Pages (from-to)e214-e227
Issue number2
Publication statusPublished - 2021

Fingerprint Dive into the research topics of 'Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a'. Together they form a unique fingerprint.

Cite this